Biology and Therapeutic Value of Mammalian Aph-1 Homologues

哺乳动物 Aph-1 同源物的生物学和治疗价值

基本信息

  • 批准号:
    6968997
  • 负责人:
  • 金额:
    $ 33.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

Presenilins (PS) form high molecular weight complexes with several other transmembrane proteins, termed NCT, Aph-1 and Pen-2 that are critical for generation of functional gamma-secretase complexes. However, the exact roles of these proteins, particularly for Aph-1 in mammals where two homologous genes exist, in regulation of gamma-secretase complex assembly remain uncertain. Although recent data support the notion that PS, NCT, Aph-1 and Pen-2 comprise the minimal gamma-secretase complex, the precise mechanism whereby these four components are assembled into the final active complex remain undefined. An interesting question is why there exist two mammalian Aph-1 genes, namely Aph-1a and Aph-1b, encoding three Aph-1 homologues called Aph-1aL, Aph-1aS and Aph-1b. Based on our recent find ings that the phenotype of Aph-1a null embryos resemble but not identical to those of Notch1 null or NCT null embryos, we hypothesize that Aph-1a is the principal mammalian Aph-1 homologue in presenilin-dependent gamma-secretase complexes required for embryonic development and that Aph-1 homologues are developmentally regulated. Thus, we plan in Aim 1 to address these issues by generation and characterization of Aph-1a null, Aph-1b null and Aph-1a+Aph-1b null mice. Based on our recent findings that the deletion of Aph-1a significantly reduces the levels of mature and immature NCT coupled with the finding that Aph-1 and NCT physically interact, we hypothesize that Aph-1 and NCT are required to regulate the stability of each other to form a stable precomplex for assembling PS and Pen-2. In such a model, we suggest that the three mammalian Aph-1 homologues (Aph-1aL, Aph-1aS and Aph-1b) define a set of six distinct functional gamma-secretase complexes. To test this model, we will generate and characterize a series of mice harboring different combination of Aph-1a and Aph-1b knockout allele and fibroblasts derived from these mice in Aim 2. Since we showed that Aph-1b null mice are viable and there is reduction in levels of PS and Pen-2 in brains of Aph-1-/- mice, we will test whether deletion of Aph-1b is sufficient to ameliorate Abeta deposition in brains of mutant APP;PS1 mice in Aim 3. Taken together, studies proposed here will address important mechanistic questions regarding physiological roles of mammalian Aph-1 homologues and critically evaluating Aph-1a and Aph-1b as therapeutic targets in efforts to ameliorate Abeta amyloidosis in AD.
早老素(PS)与其他几种跨膜蛋白形成高分子量复合物,称为NCT, Aph-1和Pen-2,这对于生成功能性γ -分泌酶复合物至关重要。然而,这些蛋白,特别是在哺乳动物中存在两个同源基因的Aph-1,在调节γ -分泌酶复合物组装中的确切作用仍然不确定。尽管最近的数据支持PS、NCT、Aph-1和Pen-2组成最小γ -分泌酶复合物的观点,但确切的机制是

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHILIP C WONG其他文献

PHILIP C WONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHILIP C WONG', 18)}}的其他基金

Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
  • 批准号:
    10477324
  • 财政年份:
    2021
  • 资助金额:
    $ 33.51万
  • 项目类别:
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
  • 批准号:
    10456359
  • 财政年份:
    2021
  • 资助金额:
    $ 33.51万
  • 项目类别:
Functional Validation of TDP-43 splicing repression for frontotemporal degeneration
TDP-43 剪接抑制对额颞叶变性的功能验证
  • 批准号:
    9926573
  • 财政年份:
    2019
  • 资助金额:
    $ 33.51万
  • 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
  • 批准号:
    10618759
  • 财政年份:
    2019
  • 资助金额:
    $ 33.51万
  • 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
  • 批准号:
    9893402
  • 财政年份:
    2019
  • 资助金额:
    $ 33.51万
  • 项目类别:
Generation and characterization of a mouse model exhibiting beta-amyloidosis and tauopathy with nuclear depletion of TDP-43
具有 TDP-43 核耗竭的 β-淀粉样变性和 tau 蛋白病小鼠模型的生成和表征
  • 批准号:
    10687257
  • 财政年份:
    2019
  • 资助金额:
    $ 33.51万
  • 项目类别:
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
ALS-FTD 中的 TDP-43 蛋白病:机制、靶标验证和生物标志物
  • 批准号:
    10583597
  • 财政年份:
    2016
  • 资助金额:
    $ 33.51万
  • 项目类别:
TDP-43 Proteinopathy in ALS-FTD: Mechanism, Target Validation and Biomarker
ALS-FTD 中的 TDP-43 蛋白病:机制、靶标验证和生物标志物
  • 批准号:
    9078756
  • 财政年份:
    2016
  • 资助金额:
    $ 33.51万
  • 项目类别:
Nicastrin: Physiological Role and Therapeutic Target Validation
尼卡斯特林:生理作用和治疗靶点验证
  • 批准号:
    6968996
  • 财政年份:
    2005
  • 资助金额:
    $ 33.51万
  • 项目类别:
Alzheimers Disease Mechanism & Experimental Therapeutic
阿尔茨海默病发病机制
  • 批准号:
    7066534
  • 财政年份:
    2005
  • 资助金额:
    $ 33.51万
  • 项目类别:

相似国自然基金

新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
  • 批准号:
    10657993
  • 财政年份:
    2023
  • 资助金额:
    $ 33.51万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10381163
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10531959
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10700991
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10518582
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10672973
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10585925
  • 财政年份:
    2022
  • 资助金额:
    $ 33.51万
  • 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
  • 批准号:
    10180000
  • 财政年份:
    2021
  • 资助金额:
    $ 33.51万
  • 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
  • 批准号:
    10049426
  • 财政年份:
    2021
  • 资助金额:
    $ 33.51万
  • 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
  • 批准号:
    10295809
  • 财政年份:
    2021
  • 资助金额:
    $ 33.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了